SELANK · 5 MG | Manejo del Estrés y Rendimiento Mental

Key Benefits of Selank GABAergic System Modulation for Anxiety Reduction Selank acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission and reducing anxiety without the sedative or dependence effects of benzodiazepines . Clinical studies have demonstrated that Selank&amp;#039;s anxiolytic activity is similar to medazepam, a benzodiazepine, but with additional antiasthenic and psychostimulant effects . Unlike benzodiazepines, Selank does not directly alter receptor affinity for GABA but modulates the number of binding sites and functional state of receptors . Enkephalin Degradation Inhibition Selank inhibits enzymes that degrade enkephalins, endogenous opioid peptides that contribute to stress and anxiety reduction . The median inhibitory concentration (IC50) for enkephalinase is approximately 15-20 μM . This inhibition prolongs enkephalin action, contributing to Selank&amp;#039;s anxiolytic and mood-regulating effects. Studies have demonstrated that serum enkephalin activity correlates with disease duration and severity of anxiety and asthenia symptoms in patients with generalized anxiety disorder . Gene Expression Regulation and Neuroplasticity Selank modulates expression of hundreds of genes involved in neurotransmission and stress response, particularly in the hippocampus, without affecting genomic activity under normal conditions . A study by Volkova et al. (2016) demonstrated that a single dose of Selank (300 µg/kg) resulted in significant changes in expression of 45 of 84 studied genes related to neurotransmission after one hour, and 22 of these genes still showed altered expression after three hours . This gene regulation effect contributes to Selank&amp;#039;s long-term effects on neuroplasticity and stress resilience. Increased Brain-Derived Neurotrophic Factor (BDNF) Selank regulates BDNF expression in the hippocampus and prefrontal cortex, promoting synaptic plasticity, learning, and memory . Studies have demonstrated that Selank increases BDNF mRNA and protein levels in the hippocampus in animal models . This effect is fundamental for maintaining long-term brain health, improving cognitive function, and protecting against stress- and age-related cognitive decline. Immune System Modulation As a tuftsin analog, Selank regulates cytokine expression, including suppression of pro-inflammatory interleukin-6 (IL-6) in patients with anxiety disorders . Studies have demonstrated that Selank at 10⁻⁷ M completely suppresses IL-6 gene expression in cultured peripheral blood cells from patients with depression, but not in cells from healthy controls . This immunomodulatory effect may contribute to reduced systemic inflammation and improved overall health. Neuroprotective and Antiapoptotic Effect Under stress conditions, Selank restores neurotrophic factor and caspase-3 levels, exerting a neuroprotective and antiapoptotic effect . This effect protects neurons from damage and cell death, maintaining long-term brain health. Studies in cerebral ischemia models have demonstrated that Selank may act at the molecular-genetic level to regulate processes triggered by ischemia

Function and Mechanism of Action of Selank Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin, an endogenous immunomodulatory peptide. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been extensively studied for its anxiolytic, nootropic, and neuroprotective properties . Its structure includes a Pro-Gly-Pro C-terminal extension that confers greater resistance to enzymatic degradation and a prolonged half-life compared to tuftsin . Detailed Mechanism of Action: Allosteric Modulation of GABA-A Receptors: Selank acts as a positive allosteric modulator of GABA-A receptors, the primary inhibitory neurotransmitter system in the brain . This modulation enhances binding of the endogenous ligand (GABA) to its receptor, increasing inhibitory neurotransmission and reducing neuronal excitability. Unlike benzodiazepines, Selank does not directly alter receptor affinity for GABA but modulates the number of binding sites and functional state of receptors . This mechanism is responsible for Selank&amp;#039;s anxiolytic effects without the sedative or dependence effects associated with benzodiazepines . Enkephalin Degradation Inhibition: Selank inhibits enzymes responsible for enkephalin degradation, endogenous opioid peptides involved in mood regulation and stress response . The IC50 for enkephalinase is approximately 15-20 μM . This inhibition prolongs enkephalin action, contributing to Selank&amp;#039;s anxiolytic and mood-regulating effects. Gene Expression Regulation: Selank modulates expression of genes involved in neurotransmission and stress response, particularly in the hippocampus . Studies have demonstrated that Selank alters expression of 45 of 84 genes related to neurotransmission in rat frontal cortex . This gene regulation effect contributes to Selank&amp;#039;s long-term effects on neuroplasticity and stress resilience. Monoamine Neurotransmitter Regulation: Selank influences concentration and metabolism of key monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine, which play crucial roles in mood regulation, cognition, and stress response . Studies have demonstrated that Selank increases serotonin metabolism in the brain stem and modulates dopamine and norepinephrine levels in various brain regions . Brain-Derived Neurotrophic Factor (BDNF) Increase: Selank regulates BDNF expression in the hippocampus and prefrontal cortex, promoting synaptic plasticity, learning, and memory . The BDNF signaling pathway is implicated in anxiety pathophysiology, and its modulation by Selank may contribute to its long-term anxiolytic and nootropic effects . Immune System Modulation: As a tuftsin analog, Selank regulates cytokine expression, including suppression of pro-inflammatory interleukin-6 (IL-6) in patients with anxiety disorders . This immunomodulatory effect may contribute to reduced systemic inflammation and improved overall health.

How to Use Selank Route of Administration: Injectable via subcutaneous (SC) or intramuscular (IM). Subcutaneous administration is the most common and preferred, as it allows gradual and constant absorption. Injection sites should be rotated (abdomen, thigh, gluteal region). Selank is also commonly administered as a nasal spray in Russian clinical practice . Reconstitution: The product is presented as a lyophilized powder in a sterile vial. It must be reconstituted with bacteriostatic water for injection (or sterile water for injection) before use. Add the diluent slowly, gently swirling the vial to dissolve the powder. Do not shake vigorously. Research Protocol: Dosage and frequency must be determined by the researcher according to protocol goals. Common research protocols for Selank use: Dose: 1-3 mg per administration (injectable) or 0.15% nasal solution (2-3 drops 4 times daily) . Frequency: 1-2 times daily (injectable) or as needed (nasal spray). Duration: Cycles of 10-20 days, repeated as needed. Research cycles of 2 to 4 weeks are recommended to assess changes in anxiety, focus, and cognitive function . Storage: The lyophilized powder should be stored in a cool, dry place, protected from light and at controlled temperature (2-8°C). Once reconstituted, it must be refrigerated (2-8°C) and used within 30 days . Important Notice: Product intended EXCLUSIVELY FOR SCIENTIFIC RESEARCH in vitro and in animal models. Not approved for human use by FDA . Selank is approved only in Russia and Belarus for generalized anxiety disorder and neurasthenia . The dosages and protocols mentioned are examples for research and do not constitute medical advice. The researcher is solely responsible for safety and compliance with applicable regulations during the development of the research protocol.

Active Ingredient: Selank (Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro): A synthetic neuropeptide analog of tuftsin that acts as an allosteric modulator of GABA-A receptors, enkephalin degradation inhibitor, and gene expression regulator . It is composed of 7 amino acids: Threonine (Thr), Lysine (Lys), Proline (Pro), Arginine (Arg), Proline (Pro), Glycine (Gly), and Proline (Pro). The active ingredient purity is ≥99% by HPLC-MS. Excipients: Mannitol: A sugar alcohol that acts as a cryoprotectant and bulking agent, used to stabilize the peptide structure during the lyophilization process. Water for Injection (WfI): High-purity water (USP/EP grade) used as a vehicle in the lyophilization process. Note for Researchers: This product is a high-purity synthetic peptide (&amp;gt;99% by HPLC-MS), manufactured without unnecessary additives, preservatives, or fillers. Its production is carried out under strict quality control standards (GMP). Selank is not FDA-approved for human use and is intended exclusively for in vitro and animal model scientific research

Onset Time &amp;amp; Expected Results of Selank Onset of Action (Minutes to Hours): Selank begins acting within the first hours after administration, with effects on anxiety and focus observed within the first days . GABAergic system modulation and enkephalin degradation inhibition occur within the first hours after administration . Measurable Benefits (1-2 Weeks): Anxiety reduction, improved focus, and mental clarity are typically the first observable effects. Studies have demonstrated that Selank produces anxiolytic effects similar to medazepam on psychometric scales within the first weeks of treatment . Selank&amp;#039;s antiasthenic and psychostimulant effects are also observable in this period . Full Effect (4-12 Weeks): For significant changes in cognitive function, neuroplasticity, and stress resilience, the full effect often requires 4-12 weeks of consistent use according to the research protocol . Studies have demonstrated that Selank&amp;#039;s effects on gene expression and BDNF regulation accumulate over time . Factors Influencing Results: The speed and magnitude of results depend on dose administered, administration frequency, subject&amp;#039;s nutritional status, age, and adherence to the research protocol. Animal model studies have demonstrated that Selank (300 µg/kg) produces significant changes in gene expression within 1-3 hours

Clinical Research &amp;amp; 3rd Party Test Results of Selank Scientific evidence on Selank is supported by clinical studies in humans and animal models, developed primarily in Russia, where the peptide is approved for generalized anxiety disorder and neurasthenia . Research has demonstrated its anxiolytic, nootropic, and neuroprotective effects. Clinical Evidence in Humans: Studies in Generalized Anxiety Disorder and Neurasthenia: A clinical study in 62 patients compared Selank (30 patients) with medazepam (32 patients). Selank produced anxiolytic activity similar to medazepam on Hamilton, Zung, and CGI scales, but with additional antiasthenic and psychostimulant effects . The study also demonstrated that Selank increased serum enkephalin activity, which correlated with anxiety reduction . Studies in Post-COVID Syndrome: A study in 64 patients with post-COVID asthenia and impaired mental performance demonstrated that Selank (nasal solution, 1.5 mg, 2-3 drops 4 times daily for 30 days) showed good effect in patients with asthenia and impaired mental performance, with parallel relief of depressive and anxiety symptoms . Studies in Phobic and Somatoform Disorders: A 2014 study in 60 patients with phobic-anxiety and somatoform disorders reported mild anxiolytic and nootropic effects of Selank, with effect persistence approximately one week after the last dose . Evidence in Animal Models: Effects on Attention and Learning: A study in rats exposed to prenatal hypoxia demonstrated that Selank (300 µg/kg, IP) increased sensory attention by 2-3 fold (p &amp;lt; 0.01) and facilitated learning capacity by 1.5 fold (p &amp;lt; 0.01), normalizing exploratory activity and restoring balance of serotonergic and noradrenergic systems . Effects on Gene Expression: A study by Volkova et al. (2016) demonstrated that a single dose of Selank (300 µg/kg) resulted in significant changes in expression of 45 of 84 genes related to neurotransmission in rat frontal cortex after one hour, and 22 of these genes still showed altered expression after three hours . Effects on BDNF: Studies have demonstrated that Selank regulates BDNF expression in rat hippocampus, with dose- and time-dependent effects . Regulatory Status: Approval in Russia and Belarus: Selank is approved in Russia and Belarus for generalized anxiety disorder and neurasthenia . FDA Classification: Selank is classified as Category 2 by FDA (substance under evaluation) and is not approved for any use in the United States . Research Use: Selank is available for in vitro and animal model scientific research. Products sold through online vendors without a prescription are not regulated by FDA . Syntex Labs Quality Standards: Lab Grade: Purity ≥99% by HPLC-MS. QR Tracking: Complete batch traceability. Secure Batch Label: &amp;quot;Scratch to See&amp;quot; security system. 3rd Party Results: Access to Certificates of Analysis (COA) from accredited external laboratories.

Product Details

SELANK · 5 MG | Manejo del Estrés y Rendimiento Mental

SELANK · 5 MG | Manejo del Estrés y Rendimiento Mental

Build Your Stack

Frequently Asked Questions